Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
50%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
4
67%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (66.7%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

terminated117%
active_not_recruiting117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
terminatedphase_2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
completedphase_2

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

NCT04847050
completednot_applicable

Influence of Hypnoacupuncture on Early Perioperative Recovery

NCT05068037
completedphase_4

Does Low Flow Anesthesia Reduce Postanaesthetic Emergence Agitation?

NCT03862391
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04743661Phase 2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active Not Recruiting
NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated
NCT04847050Phase 2

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Completed
NCT05068037Not Applicable

Influence of Hypnoacupuncture on Early Perioperative Recovery

Completed
NCT03862391Phase 4

Does Low Flow Anesthesia Reduce Postanaesthetic Emergence Agitation?

Completed
NCT00401388Phase 2

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6